ANEMOCYTE - Trademark Details
Status: 700 - Registered
Serial Number
79211373
Registration Number
5440621
Word Mark
ANEMOCYTE
Status
700 - Registered
Status Date
2018-04-10
Filing Date
2017-02-06
Registration Number
5440621
Registration Date
2018-04-10
Mark Drawing
5000 - Illustration: Drawing with word(s)/letter(s)/number(s) in Stylized form
Typeset
Published for Opposition Date
2018-01-23
Attorney Name
Law Office Assigned Location Code
N10
Employee Name
EVANKO, PATRICIA MALES
Statements
Indication of Colors claimed
The color(s) light blue, green, blue, light grey and dark grey is/are claimed as a feature of the mark.
Description of Mark
The mark consists of the following: the stylized term "ANEMOCYTE" with the letters "ANEM" and "YTE" appearing in dark grey, and the letters "OC" merged and appearing in light blue, green, blue and light grey.
Goods and Services
Pharmaceutical and veterinary preparations, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for use in human and veterinary medicine; chemical preparations for pharmaceutical or medical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco skeletal, metabolic diseases, dermatology; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, products for gene therapy, namely, genetically modified cells, viral vectors, nucleic acids; tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy
Goods and Services
Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; medical information and data on research and development in the medical and veterinary fields; scientific and technological services, namely, scientific research and, literature scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology, consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2017-07-08
Primary Code
005
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2017-07-08
Primary Code
042
Current Trademark Owners
Party Name
Party Type
30 - Original Registrant
Legal Entity Type
16 - Limited Liability Company
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
30 - Original Registrant
Legal Entity Type
16 - Limited Liability Company
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
16 - Limited Liability Company
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
16 - Limited Liability Company
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Julie B. Seyler
Address
Please log in with your Justia account to see this address.
International Registrations
International Registration Number
1353452
International Registration Date
2017-02-06
International Publication Date
2017-07-06
International Renewal Date
2027-02-06
Auto Protection Date
2019-01-06
International Status
001 - Request for extension of protection established
International Status Date
2017-07-06
Priority Claimed In
True
Priority Claimed Date
2017-01-17
First Refusal In
True
Trademark Events
Event Date | Event Description |
2017-07-06 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
2017-07-07 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
2017-07-08 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2017-07-08 | ASSIGNED TO EXAMINER |
2017-07-11 | NON-FINAL ACTION WRITTEN |
2017-07-12 | APPLICATION FILING RECEIPT MAILED |
2017-07-12 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
2017-07-18 | REFUSAL PROCESSED BY MPU |
2017-07-18 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
2017-08-04 | REFUSAL PROCESSED BY IB |
2017-10-20 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
2017-10-20 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
2017-12-11 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2017-12-11 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2017-12-11 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2017-12-11 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2018-01-03 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2018-01-03 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
2018-01-03 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
2018-01-23 | PUBLISHED FOR OPPOSITION |
2018-01-23 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2018-02-10 | NOTIFICATION PROCESSED BY IB |
2018-02-22 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
2018-04-10 | REGISTERED-PRINCIPAL REGISTER |
2018-07-10 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
2018-07-16 | FINAL DISPOSITION PROCESSED |
2018-07-16 | FINAL DISPOSITION NOTICE SENT TO IB |
2018-08-11 | FINAL DECISION TRANSACTION PROCESSED BY IB |
2021-04-09 | NEW REPRESENTATIVE AT IB RECEIVED |